Neuronal Acetylcholine Receptor Subunit Beta 2, Pipeline Review, H2 2019: Assuage Pharmaceuticals Inc & Kyung Dong Co. Ltd – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Neuronal Acetylcholine Receptor Subunit Beta 2 – Pipeline Review, H2 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Summary

According to the recently published report ‘Neuronal Acetylcholine Receptor Subunit Beta 2 – Pipeline Review, H2 2019’; Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) pipeline Target constitutes close to 9 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes.

Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) – Neuronal acetylcholine receptor subunit beta-2 is a protein encoded by the CHRNB2 gene. Acetylcholine binds to this receptor. This results in extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeable to sodium ions.

The report ‘Neuronal Acetylcholine Receptor Subunit Beta 2 – Pipeline Review, H2 2019’ outlays comprehensive information on the Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 3, 2 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System which include indications Smoking Cessation, Psychiatric Disorders, Alcohol Addiction, Major Depressive Disorder, Neurology and Nicotine Addiction.

Scope

• The report provides a snapshot of the global therapeutic landscape for Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2)
• The report reviews Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) targeted therapeutics and enlists all their major and minor projects
• The report assesses Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) targeted therapeutics

Reasons to buy

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Key Topics Covered:

• Introduction
• Report Coverage
• Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) – Overview
• Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) – Therapeutics Development
• Products under Development by Stage of Development
• Products under Development by Therapy Area
• Products under Development by Indication
• Products under Development by Companies
• Products under Development by Universities/Institutes
• Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) – Therapeutics Assessment
• Assessment by Mechanism of Action
• Assessment by Route of Administration
• Assessment by Molecule Type
• Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) – Companies Involved in Therapeutics Development
• Assuage Pharmaceuticals Inc
• H. Lundbeck AS
• Jeil Pharmaceutical Co Ltd
• Kyung Dong Co Ltd
• Sopharma AD
• Suven Life Sciences Ltd
• Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) – Drug Profiles
• AP-202 – Drug Profile
• cytisinicline – Drug Profile
• JLP-1603 – Drug Profile
• KD-8001 – Drug Profile
• Small Molecule to Antagonize CHRNB2 and CHRNA4 for Psychiatric Disorders – Drug Profile
• Small Molecules to Antagonize CHRNA4 and CHRNB2 for Neurological and Psychiatric disorders – Drug Profile
• Small Molecules to Antagonize CHRNB2 and CHRNA4 for Smoking Cessation – Drug Profile
• SUVN-911 – Drug Profile
• varenicline tartrate – Drug Profile
• varenicline tartrate – Drug Profile
• Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) – Dormant Products
• Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) – Discontinued Products
• Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) – Product Development Milestones
• Featured News & Press Releases

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/646s23

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900